Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials by unknown
Grill et al. Alzheimer's Research & Therapy  (2015) 7:39 
DOI 10.1186/s13195-015-0122-5RESEARCH Open AccessComparing recruitment, retention, and safety
reporting among geographic regions in
multinational Alzheimer’s disease clinical trials
Joshua D Grill1*, Rema Raman2, Karin Ernstrom2, Paul Aisen2, Sherie A Dowsett3, Yun-Fei Chen3, Hong Liu-Seifert3,
Ann Marie Hake3, David S Miller4, Rachelle S Doody5, David B Henley3 and Jeffrey L Cummings6Abstract
Introduction: Most Alzheimer’s disease (AD) clinical trials enroll participants multinationally. Yet, few data exist to
guide investigators and sponsors regarding the types of patients enrolled in these studies and whether participant
characteristics vary by region.
Methods: We used data derived from four multinational phase III trials in mild to moderate AD to examine whether
regional differences exist with regard to participant demographics, safety reporting, and baseline scores on the Mini
Mental State Examination (MMSE), the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-cog11),
the Clinical Dementia Rating scale Sum of Boxes (CDR-SB), the Alzheimer’s Disease Cooperative Study–Activities of Daily
Living Inventory (ADCS-ADL), and the Neuropsychiatric Inventory (NPI). We assigned 31 participating nations to 7
geographic regions: North America, South America/Mexico, Western Europe/Israel, Eastern Europe/Russia, Australia/
South Africa, Asia, and Japan.
Results: North America, Western Europe/Israel, and Australia/South Africa enrolled similar proportions of men,
apolipoprotein E ε4 carriers, and participants with spouse study partners, whereas Asia, Eastern Europe/Russia, and
South America/Mexico had lower proportions for these variables. North America and South America/Mexico enrolled
older subjects, whereas Asia and South America/Mexico enrolled less-educated participants than the remaining regions.
Approved AD therapy use differed among regions (range: 73% to 92%) and was highest in North America, Western
Europe/Israel, and Japan. Dual therapy was most frequent in North America (48%). On the MMSE, North America,
Western Europe/Israel, Japan, and Australia/South Africa had higher (better) scores, and Asia, South America/Mexico,
and Eastern Europe/Russia had lower scores. Eastern Europe/Russia had more impaired ADAS-cog11 scores than all
other regions. Eastern Europe/Russia and South America/Mexico had more impaired scores for the ADCS-ADL and the
CDR-SB. Mean scores for the CDR-SB in Asia were milder than all regions except Japan. NPI scores were lower in Asia
and Japan than in all other regions. Participants in North America and Western Europe/Israel reported more adverse
events than those in Eastern Europe/Russia and Japan.
Conclusions: These findings suggest that trial populations differ across geographic regions on most baseline
characteristics and that multinational enrollment is associated with sample heterogeneity. The data provide initial
guidance with regard to the regional differences that contribute to this heterogeneity and are important to
consider when planning global trials.* Correspondence: grill@uci.edu
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Alzheimer’s disease (AD) is a worldwide pandemic. Between
1990 and 2010, the global health care burden caused by AD
increased 244% [1]. The rapid increases in prevalence and
cost have led several countries to develop national plans to
address AD [2]. A goal of these plans is to advance research
toward improved therapies and, in particular, drugs capable
of slowing the course of the disease and delaying its on-
set if their use is initiated early enough. Key to developing
improved AD therapies will be the conduct of robust clin-
ical trials. AD trials present many challenges, including
slow recruitment.
Most AD trials are now multinational [3,4]. Multinational
trials enable expedited recruitment and are necessary to
secure multinational regulatory registration and eventual
patient access [5]. Yet, these trials may also bring ethical,
logistical, and scientific challenges. Trials are usually con-
ducted only in regions in which the drug, if approved, is
available [6]. Some countries have instituted laws intended
to protect citizens that may impede research conduct, and
sponsors must negotiate local regulatory issues [7]. Trans-
lated study materials may introduce instructional and
cultural inaccuracies, resulting in excess psychometric
variance and reduced data integrity [8]. Global and ethnic
variation in drug pharmacokinetics or pharmacodynamics
may impact drug safety or efficacy [9,10].
For AD trials specifically, local laws, ethical guidelines,
or practices regarding surrogate consent may vary among
geographic regions [11,12]. Regional or cultural differ-
ences may affect whether and when a diagnosis is
made, who provides care, and the availability of ap-
proved therapeutic options [13]. These and other fac-
tors could introduce heterogeneity into AD trial samples
and should be considered when implementing multi-
national trials.
Despite the widespread dependence on multinational
trials, there is little in the way of a “science of globalization”
to inform decisions. To help address this information
gap, we examined the baseline characteristics of trial
participants across seven geographic regions in four
multinational, phase III, industry-sponsored trials with
patients with mild to moderate AD. We examined demo-
graphic as well as disease- and trial-related variables across
geographic regions and compared regions for differences
in the frequency of reported adverse events and participant
study completion. For all outcomes, we tested the null
hypothesis that geographic regions do not differ from
each other in the setting of multinational AD trials. These
exploratory analyses were conducted with the intention
of generating data-based observations of participant
characteristics and safety reporting across regions that
may be helpful in trial planning. Measures of disease
progression and the implications of these observations
for trial planning and policy are reported separately.Methods
Data source
These results describe a combined dataset from four multi-
national, phase III clinical trials conducted in mild to mod-
erate AD. The results of the primary efficacy analyses from
these trials have been reported elsewhere [14,15]. We
analyzed data from two trials each of two investigational
compounds, the γ-secretase inhibitor semagacestat [16-20]
(the IDENTITY program: ClinicalTrials.gov identifiers
NCT00762411 and NCT01035138) and the humanized
monoclonal anti-amyloid-β (anti-Aβ) antibody solanezu-
mab [21,22] (the EXPEDITION program: ClinicalTrials.-
gov identifiers NCT00905372 and NCT00904683). Each
trial was sponsored by Eli Lilly & Company, and data were
analyzed by the Alzheimer’s Disease Cooperative Study
(ADCS) group members through its Data Analysis and
Publication Committee. For each analysis, all available
data were used.
Trial inclusion and exclusion criteria
The four trials used nearly identical inclusion and exclu-
sion criteria, though they varied according to the type of
therapy under investigation. The semagacestat trials re-
quired the ability to swallow oral medications, and the sola-
nezumab trials required good venous access for delivery of
intravenous therapy and excluded those with allergies to
humanized monoclonal antibodies. The solanezumab, but
not semagacestat, trials excluded patients with a history of
repeated head trauma over the previous 5 years.
Participants were at least 55 years of age and met
National Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association criteria for probable AD [23].
Mild to moderate AD was defined as a score of 16 to
26 (inclusive) on the Mini Mental State Examination
(MMSE) [24]. Participants were permitted to receive
background cholinesterase inhibitors and/or memantine if
the treatment was initiated at least 4 months prior to
screening and was stable in dose for at least 2 months.
They had to have had magnetic resonance imaging (MRI)
or computed tomography (CT) results within the previous
2 years that were not inconsistent with a diagnosis of AD.
Those without imaging had MRI and/or CT at screening.
All participants had a reliable caregiver who was in fre-
quent contact with them (defined as ≥10 hours per week),
accompanied them to site visits or was available by
telephone, and monitored administration of prescription
medications during the trial.
Participants were excluded if they had a Geriatric De-
pression Scale score >6, if they had a Hachinski Ischemic
Score >4, or if they met the National Institute of Neuro-
logical Disorders and Stroke/Association Internationale
pour la Recherche et l’Enseignement en Neurosciences
criteria for vascular dementia [25]. Patients with serious
Grill et al. Alzheimer's Research & Therapy  (2015) 7:39 Page 3 of 15or unstable medical conditions (including HIV) or a
history within the last 5 years of serious central nervous
system infection, primary or recurrent malignant dis-
ease (with the exception of resected cutaneous in situ
squamous or basal cell carcinoma or in situ cervical or
prostate cancer with normal prostate-specific antigen
posttreatment), or chronic alcohol or drug abuse were
excluded. Previous exposure to either the agent under
study or an Aβ vaccine or monoclonal antibody was
not permitted.
Outcome measures
We examined the effect of geographic region on screening
and baseline clinical outcome measures that are common
to AD trials. A centralized company translated outcome
measures into the appropriate language of the region of
each site.
The MMSE is a global cognition measure that requires
approximately 10 minutes to administer and is the most
common tool for determining trial eligibility. Its items
are used to assess short-term memory, orientation, calcu-
lation, language interpretation, naming, and praxis. The
MMSE has a range of 0 to 30, with higher scores
representing better performance. We investigated MMSE
scores at screening and baseline.
The Alzheimer’s Disease Assessment Scale–Cognitive
subscale (ADAS-cog) is the only cognitive outcome meas-
ure that has been used to successfully demonstrate drug
efficacy in mild to moderate AD registration trials. It was
one of the co-primary outcomes for each of the four trials
included in our present analysis. The ADAS-cog typically
includes 11 subtests that assess the patient’s memory,
orientation, comprehension, naming, word finding, and
ideational and constructional praxis [26]. The range is
0 to 70, with higher scores representing greater cognitive
impairment. We assessed baseline scores on the 11-item
ADAS-cog (ADAS-cog11).
The Alzheimer’s Disease Cooperative Study Activities
of Daily Living Inventory (ADCS-ADL) was the other
co-primary outcome measure for the four trials. The scale
is informant-based and is used to assess basic and instru-
mental activities of daily living. Scores range from 0 to
78, with higher scores representing greater functional
independence [27]. We examined ADCS-ADL scores at
baseline.
The Clinical Dementia Rating scale Sum of Boxes
(CDR-SB) was a secondary outcome measure in each trial.
The CDR is a global instrument that includes separate in-
terviews of the patient and the informant. The investi-
gator uses the interviews to assign severity scores (0,
not demented; 0.5, questionable dementia; 1.0, mild de-
mentia; 2.0, moderate dementia; or 3.0, severe dementia)
for each of six “boxes,” including memory, orientation,
judgment and problem solving, community affairs, homeand hobbies, and self-care [28]. We examined the Sum of
Boxes scores at baseline.
The Neuropsychiatric Inventory (NPI) is the most widely
used scale for examining behavioral symptoms in the
setting of AD trials. The study partner is asked to report
the frequency and severity of 12 behavioral symptoms ob-
served over the previous 4 weeks [29,30]. Each domain is
assessed as present or absent. If present, the severity (1 to
3 points) and frequency (1 to 4 points) are scored. The se-
verity and frequency are multiplied, and the scores across
domains are summed for a total range of 0 to 144, with
higher scores representing greater behavioral symptoms.
Raters who failed to meet minimum experience re-
quirements for the outcome measures were required to
participate in an enriched training program, including
additional online and live training. All raters underwent
live training on outcome measures at the principal inves-
tigator’s meeting and were required to pass qualification
assessments on the co-primary outcome scales. As part
of an in-study rating review program, screening MMSE
in both study programs and ADAS-cog at baseline
and 12 weeks (EXPEDITION program) or 52 weeks
(IDENTITY program) were reviewed for scoring errors;
raters underwent remedial training when indicated; and
errors were subsequently corrected.
Data analyses
Patients were enrolled in 31 different countries. Investiga-
tive sites were chosen after a careful feasibility assessment
of experience in caring for patients with AD, experience in
running AD trials, and experience of raters in adminis-
tering the trial outcome measures. On the basis of the
country of enrollment, participants were categorized
into one of seven geographic regions: North America
(United States and Canada), South America/Mexico
(Argentina, Brazil, Chile, and Mexico), Western Europe/
Israel (Belgium, Denmark, Finland, France, Germany,
Israel, Italy, Spain, Sweden, and United Kingdom), Eastern
Europe/Russia (Bulgaria, Hungary, Poland, Romania, Russia,
Serbia, Turkey, and Ukraine), Australia/South Africa, Asia
(China, India, Korea, and Taiwan), and Japan. We based our
regional assignments on the work of Glickman and col-
leagues [5], who grouped patients in parts of the world
with shared culture, history, geography, and linguistic
features. Definitions were modified to allow combination
of some countries that contained small samples due to
participation in only one study program.
Data for drug and placebo-assigned participants from
all four trials were included in the baseline data analyses
(demographic summaries and screening and baseline scores
on outcome measures). Mean age and level of education
were quantified in years. We also examined the proportion
of each region with varying levels of education: <8 years, 8
to 12 years, and >12 years. Mean height in centimeters and
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(BMI; weight divided by height squared) was calculated for
each participant. Participants who carried one or more cop-
ies of the ε4 allele of the apolipoprotein E (APOE) genotype
were categorized as ε4 carriers. Participant study partners
were categorized as spouse, adult child, or other at baseline.
Study retention and treatment-emergent adverse event
(TEAE) and serious adverse event (SAE) reporting were
examined separately by study program (IDENTITY or
EXPEDITION) and by treatment group assignment
(semagacestat, solanezumab, or placebo).
Study retention was defined as fulfilling all eligible visits.
In the IDENTITY program, semagacestat dosing was
halted prior to study completion. The studies were
amended to follow study participants for 7 months after
discontinuing semagacestat, but these data are not included
in the present analyses. Because of this amendment, how-
ever, some participants are included as “completers” (that
is, retained for all eligible visits), despite participating for
less than the protocol-defined 18-month study period.
TEAEs were defined as adverse events that first occurred
or worsened in severity compared with their maximum se-
verity during the baseline period (between screening
and baseline visits). We examined TEAE reporting in each
study program for the placebo groups and for the higher-
dose arms of each active drug (semagacestat 140 mg by
mouth daily and solanezumab 400 mg intravenously every
4 weeks). To account for differences in time to site
startup and differences in the time for trial conduct (the
IDENTITY trials were amended to stop semagacestat
prior to completion), TEAEs were reported as per patient
per month. We also examined the proportion of TEAEs
reported as SAEs among the regions.
Descriptive statistics are presented as mean ± standard
deviation for continuous variables and count (%) for cat-
egorical variables, unless otherwise stated. For continu-
ous baseline variables in which assumptions of normality
were met, analysis of variance (ANOVA) and Levene’s test
were used to examine the overall impact of geographic re-
gion. If the assumptions were not met, the Kruskal-Wallis
test was performed. Categorical baseline variables, TEAE
reporting, and study retention were compared across geo-
graphical regions using a χ2 test for independence. For
variables in which an overall significant effect of region
was present, pairwise comparisons between regions were
performed using Tukey’s honestly significant difference
(HSD) test (with the ANOVA), the Wilcoxon rank-sum
test with the Holm’s adjustment for multiple comparisons
(with the Kruskal-Wallis test), and χ2 test using the Holm’s
adjustment for multiple comparisons (with the χ2 test).
We report significant differences if they reached a
conservative significance level of P < 0.01. Statistical
analysis was conducted using R version 2.14.0 statistical
software [31].Ethics
For each trial, informed consent was provided by the
participant or a legally authorized representative, in ac-
cordance with local regulations, and only after approval
by the site’s institutional review board of record. The
present study analyzing data collected across these clin-
ical trials was reviewed by the University of California,
Los Angeles Medical Institutional Review Board 3 and




In total, data from 4,694 participants were included in
these analyses. Forty percent of all participants were en-
rolled in North America. The next highest enrolling re-
gion was Western Europe/Israel, with 981 participants
(21%) enrolled. No other region enrolled more than 10%
of the overall sample across trials (Table 1). We observed
regional differences for each demographic variable exam-
ined (age: P < 0.0001 by ANOVA; weight: P < 0.001 by
Kruskal-Wallis test; height: P < 0.001 by Kruskal-Wallis
test; body mass index: P < 0.001 by Kruskal-Wallis test;
sex: P < 0.001 by χ2 test; education: P < 0.001 by Kruskal-
Wallis test; APOE genotype: P < 0.001 by χ2 test; study
partner type: P < 0.001 by χ2 test).
In pairwise comparisons, participants enrolled in North
America and South America/Mexico were older than
those enrolled in every other region (Table 1). Partici-
pants enrolled in Eastern Europe/Russia were the youn-
gest (P < 0.001 for all comparisons except vs Australia/
South Africa (P = 0.011), Western Europe/Israel (P = 0.09),
and Asia (P = 0.20), all by Tukey’s HSD test).
North American participants were taller than participants
from every other region (P < 0.001 by paired Wilcoxon
rank-sum test with Holm’s adjustment) except Australia/
South Africa and Western Europe/Israel and heavier than
participants from every other region (P < 0.001) except
Australia/South Africa (Table 1). Japanese participants
were lighter, shorter, and had lower BMIs than participants
from every other region (P < 0.001). Excluding Japan, Asian
participants were lighter, shorter, and had lower BMIs than
those in the remaining regions (P < 0.001 for all compari-
sons except vs South America/Mexico).
In every region, more women than men were enrolled.
In South America/Mexico, 68% of participants were fe-
male, the highest proportion of any region (P < 0.01 vs
Australia/South Africa, North America, and Western
Europe/Israel and P = 0.02 vs Asia, both by χ2 test with
Holm’s adjustment). Western Europe/Israel, North America,
and Australia/South Africa enrolled the highest proportions
of male participants.
The range of education among participants was 0 to
29 years, with an overall median education level of 12
Table 1 Regional demographic and disease-related summaries of the participants at baselinea
North America Western Europe Australia/South
Africa






N (%) 1,884 (40.1) 981 (20.9) 237 (5.1) 435 (9.3) 339 (7.2) 408 (8.7) 410 (8.7) 4,694 (100)
Age, yr (mean ± SD) 75.1 ± 8.3EE,AS,JP,AU,WE 71.9 ± 7.8SA,JP 72.9 ± 7.4SA,EE,NA 73.4 ± 7.6SA,NA 72.1 ± 7.6SA,NA 70.7 ± 7.8SA,AU,NA 75.4 ± 7.7EE,AS,JP,AU,WE 73.6 ± 8.1
Female sex, n (%) 986 (52.3)SA,EE,JP 503 (51.3) SA,EE,JP 128 (54.0)SA 276 (63.5)WE,NA 191 (56.3) 255 (62.5)WE,NA 279 (68.1)AU,WE,NA 2,618 (55.8)
Height, cm
(mean ± SD)
166.5 ± 10.7SA,EE,AS,JP 166.1 ± 9.8SA,EE,AS,JP 166.8 ± 9.7SA,EE,AS,JP 154.6 ± 8.9SA,EE,AS,AU,WE,NA 158.2 ± 8.6EE,JP,AU,WE,NA 163.4 ± 9.1SA,AS,JP,AU,WE,NA 160.0 ± 9.1EE,JP,AU,WE,NA 163.9 ± 10.7
Weight, kg
(mean ± SD)
73.2 ± 15.7SA,EE,AS,JP,WE 70.2 ± 12.7SA,AS,JP,NA 70.7 ± 13.1SA,AS,JP 53.1 ± 10.0SA,EE,AS,AU,WE,NA 58.5 ± 9.7SA,EE,JP,AU,WE,NA 68.8 ± 12.6AS,JP,NA 66.6 ± 12.5AS,JP,AU,WE,NA 68.6 ± 15.0
Body mass index,
kg/m2 (mean ± SD)
26.3 ± 4.7AS,JP,WE 25.4 ± 3.8AS,JP,NA 25.4 ± 4.1AS,JP 22.1 ± 3.1SA,EE,AS,AU,WE,NA 23.3 ± 3.1SA,EE,JP,AU,WE,NA 25.4 ± 3.8AS,JP 26.0 ± 4.3AS,JP 25.4 ± 4.4
Years of education
(mean ± SD)
14.1 ± 3.3SA,EE,AS,JP,AU,WE 11.2 ± 4.2SA,EE,AS,NA 12.1 ± 3.5SA,AS,WE,NA 11.7 ± 2.7SA,AS,NA 9.5 ± 4.7EE,JP,AU,WE,NA 11.9 ± 3.8SA,AS,WE,NA 8.9 ± 4.5EE,JP,AU,WE,NA 12.2 ± 4.1
APOE ε4 genotype
carriers, n (%)
1,086 (63.2)SA,EE,AS,JP 494 (63.3)SA,EE,AS,JP 149 (63.7)SA 220 (51.9)WE,NA 93 (48.4)WE,NA 191 (51.1)WE,NA 189 (49.5)AU,WE,NA 2,422 (59.0)
Years since symptom
onset (mean ± SD)
4.8 ± 2.6EE,AS,JP 4.6 ± 2.5EE,JP 4.7 ± 2.8EE,JP 3.7 ± 2.3SA,AS,AU,WE,NA 4.2 ± 2.4JP,NA 3.9 ± 2.2SA,AU,WE,NA 4.5 ± 2.4EE,JP 4.5 ± 2.5
Years since diagnosis
(mean ± SD)












1,318 (70.4)SA,EE,AS 719 (73.7)SA,EE,AS 178 (75.7)SA,EE,AS 279 (64.6)SA,EE,AS 172 (50.9)JP,AU,WE,NA 163 (40.1)JP,AU,WE,NA 174 (42.7)JP,AU,WE,NA 3,003 (64.4)
Proportion enrolling
with adult child study
partner, n (%)




179 (9.6) 64 (6.6) 21 (8.9) 37 (8.6) 30 (8.9) 41 (10.1) 72 (17.7) 444 (9.5)
aSA = P < 0.01 vs South America/Mexico; EE = P < 0.01 vs Eastern Europe/Russia; AS = P < 0.01 vs Asia; JP = P < 0.01 vs Japan; AU = P < 0.01 vs Australia/South Africa; WE = P < 0.01 vs Western Europe; NA = P < 0.01 vs
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America had higher education than participants from
all other regions, with 60% of participants having >12
years and <3% of participants having <8 years (data not
shown). Japan had a similar low proportion of partici-
pants with <8 years of education (2.8%), but the major-
ity of Japanese participants (74.7%) had <12 years.
Participants from South America/Mexico (mean = 8.9
years) and Asia (mean = 9.5 years) had less education
than all other regions (Table 1). These regions had sub-
stantially higher proportions of participants with <8
years of education (39% for Asia and 49% for South
America/Mexico; data not shown) than all other regions.
Fifty-nine percent of all participants carried at least
one copy of APOE ε4. The proportions of APOE ε4 car-
riers ranged from 48.4% (Asia) to 63.7% (Australia/South
Africa). North America, Western Europe/Israel, and
Australia/South Africa had the highest proportions of
APOE ε4 carriers (P < 0.01 by χ2 test with Holm’s ad-
justment for all comparisons to North America and
Western Europe/Israel) (Table 1).
In North America, Western Europe/Israel, and Australia/
South Africa, >70% of participants were enrolled with a
spouse study partner. In contrast, the majority of partici-
pants in Eastern Europe/Russia (60%) and South America/
Mexico (57%) were enrolled with a nonspouse study
partner. In Eastern Europe/Russia, 50% of participants
were enrolled with an adult child, and in South America/
Mexico, 18% of participants were enrolled with a study
partner who was neither a spouse nor an adult child—-
higher proportions, respectively, than any other region.Disease-related variables
Geographic regions differed in the time since symptom
onset and time between diagnosis and trial enrollment
(P < 0.001 for both variables by Kruskal-Wallis test). The
overall mean duration of symptoms prior to enrollment
was 4.5 ± 2.5 years. This duration was significantly shorter
in Japan and Eastern Europe/Russia than all other regions
except Asia (P < 0.01 for all comparisons except Eastern
Europe/Russia vs Asia) (Table 1). North America had the
longest duration of symptoms prior to enrollment, though
the difference reached statistical significance only when
compared with Japan, Eastern Europe/Russia, and Asia.
The mean time from diagnosis to enrollment was approxi-
mately 2.0 to 2.5 years shorter than the time since symp-
tom onset for each region, with a pattern of pairwise
differences similar to that observed for time since symp-
tom onset. Eastern Europe/Russia and Japan had the
shortest duration of time since diagnosis (P < 0.01 for
all comparisons except Japan vs Asia) (Table 1). North
America had longer duration of time since diagnosis
than all other regions except South America/Mexico.Across geographic regions, a large majority (86.5%) of
participants were taking at least one US Food and Drug
Administration–approved anti-AD medication. Among
AD medications, donepezil was most common; 52% of
all participants were taking donepezil at the time of screen-
ing. Anti-AD drug use at screening varied significantly
among geographic regions, however (χ2; P = 0.0001 by χ2
test). Anti-AD drug use was highest in Western Europe/
Israel, North America, and Japan (P < 0.01 for comparisons
to remaining regions except North America vs South
America/Mexico (P = 0.019) and Japan vs Asia (P = 0.012)).
Memantine use was less common than cholinesterase in-
hibitor therapy; 32% of participants were taking memantine
and 27% were on dual therapy at the time of screening.
Both memantine and dual therapy rates differed among
the regions (P < 0.0001 by χ2 test). More participants in
North America than in any other region were on dual ther-
apy. Fewer participants in Japan than in any other region
were on dual therapy.
Baseline outcome measure scores
Scores on cognitive, functional, and behavioral outcomes
at screening and baseline visits differed among the re-
gions (P < 0.0001 for each outcome measure by Kruskal-
Wallis test). Despite the study inclusion criteria (MMSE
score between 16 and 26), the range of MMSE scores
observed at screening was 13 to 27. Only Japan and
Western Europe/Israel did not enroll a participant with
a screening MMSE score outside the inclusion criteria,
though no region exceeded 1% of scores out of range at
screening. Higher mean MMSE scores at screening were ob-
served in North America, Western Europe/Israel, Australia/
South Africa, and Japan relative to the remaining regions
(Table 2). The mean MMSE scores and patterns of regional
differences at baseline remained largely the same as at
screening, but the variance increased in each region at
baseline (Table 2). The range of MMSE scores at the
baseline visit was from 6 to 30. Overall, 7.5% of all
baseline visit scores were outside the screening range of
16 to 26. Eleven percent of baseline visit MMSE scores
in North America and 9.5% in Asia were outside the
screening entry criteria.
Baseline scores on the ADAS-cog11 ranged from 3 to
68. Mean scores in North America, Australia/South Africa,
and Japan were significantly milder than those for all
remaining regions (P < 0.01 for all comparisons except
Australia/South Africa vs Western Europe/Israel (P =
0.09)). Eastern Europe/Russia demonstrated signifi-
cantly higher scores than all remaining regions (P < 0.01
for all comparisons except vs South America/Mexico
(P = 0.03)).
Participants from Eastern Europe/Russia and South
America/Mexico performed worse (greater disease se-
verity) than those from all other regions for both the
Table 2 Baseline scores across regionsa
North America Western Europe Australia/South
Africa
Japan Asia Eastern Europe/Russia South America/Mexico Total sample
MMSE at screen,
mean ± SD
21.0 ± 3.2SA,EE,AS 21.0 ± 3.1SA,EE,AS 21.0 ± 3.0SA,EE,AS 20.9 ± 2.9SA,EE,AS 19.8 ± 3.1JP,AU,WE,NA 20.1 ± 3.0JP,AU,WE,NA 20.2 ± 3.0JP,AU,WE,NA 20.8 ± 3.1
MMSE at baseline,
mean ± SD
21.0 ± 3.7SA,EE,AS 20.9 ± 3.4SA,EE,AS 20.8 ± 3.4AS 20.9 ± 3.3AS 19.8 ± 3.4JP,AU,WE,NA 20.3 ± 3.1WE,NA 20.3 ± 3.1WE,NA 20.7 ± 3.5
ADAS-cog11, mean ± SD 22.0 ± 8.9SA,EE,AS,WE 23.4 ± 8.9SA,EE,JP,NA 21.9 ± 9.2SA,EE,AS 21.4 ± 6.7SA,EE,AS,WE 24.1 ± 7.9EE,JP,AU,NA 27.3 ± 10.7AS,JP,AU, WE,NA 25.0 ± 8.8JP,AU,WE,NA 23.1 ± 9.0
ADCS-ADL, mean ± SD 62.4 ± 11.7SA,EE,AS,JP,WE 59.3 ± 13.3SA,EE,NA 59.6 ± 13.3SA,EE 60.2 ± 11.4SA,EE,NA 56.5 ± 14.5SA,EE,NA 50.9 ± 15.7AS,JP, AU, WE,NA 53.3 ± 14.4AS,JP,AU, WE,NA 59.2 ± 13.5
CDR-SB, mean ± SD 5.1 ± 2.5SA,EE,AS 5.3 ± 2.6SA,EE,AS 5.5 ± 2.6SA,EE,AS 5.1 ± 2.8SA,EE 4.7 ± 2.6SA,EE,AU,WE,NA 7.0 ± 3.2AS,JP,AU, WE,NA 6.4 ± 2.9AS,JP,AU,WE,NA 5.4 ± 2.7
NPI, mean ± SD 9.2 ± 10.9SA,JP,AU, WE 10.5 ± 11.3AS,JP,NA 11.9 ± 12.1AS,JP,NA 6.6 ± 8.6SAEE,AU,WE,NA 7.7 ± 9.2SA,EE,AU,WE 10.7 ± 11.6AS,JP 11.9 ± 12.1AS,JP,NA 9.6 ± 11.0
aSA = P < 0.01 vs South America/Mexico; EE = P < 0.01 vs Eastern Europe/Russia; AS = P < 0.01 vs Asia; JP = P < 0.01 vs Japan; AU = P < 0.01 vs Australia/South Africa; WE = P < 0.01 vs Western Europe; NA = P < 0.01 vs
North America; ADAS-cog11 = 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale;; ADCS-ADL = Alzheimer’s Disease Cooperative Study–Activities of Daily Living Inventory; CDR-SB = Clinical Dementia
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sons by Wilcoxon rank-sum test). ADCS-ADL scores in
North America were higher (less functional impairment)
than in all other regions (P < 0.01 by Wilcoxon rank-sum
test for all comparisons except Australia/South Africa
(P = 0.015)). Mean CDR-SB scores in Asia were milder
than in all regions except Japan (P < 0.01 for all com-
parisons by Wilcoxon rank-sum test).
Australia/South Africa and South America/Mexico
had the highest NPI scores at baseline (greater neuro-
psychiatric symptomatology). Japan had significantly lower
scores than all other regions except Asia (P < 0.01 for all
comparisons by Wilcoxon Rank Sum test) (Table 2).
Treatment-emergent adverse event reporting
The overall reporting of TEAEs for the four examined
datasets was 77% for the IDENTITY program placebo
arms, 89% for the IDENTITY semagacestat arms, 84%
for the EXPEDITION placebo arms, and 81% for the
EXPEDITION solanezumab arms. TEAE reporting among
regions ranged from 57% for Eastern Europe/Russia in the
IDENTITY program placebo arms to 95% for North
America in the IDENTITY 140-mg dose semagacestat
arms. TEAE reporting normalized by time and participant
differed among regions for each dataset (P < 0.0001 for all
by χ2 test), and the observed geographic patterns were
similar for both agents and both placebo datasets. North
America and Western Europe/Israel performed similarly
and had significantly more reported TEAEs than Eastern
Europe/Russia and Japan in most datasets (Table 3). Asia
and Eastern Europe/Russia performed similarly in most
analyses and had fewer TEAEs. There were no differences
between regions in TEAEs severe enough to lead to dis-
continuation (Table 4).
The overall reporting of SAEs was 12% for the IDENTITY
program placebo arms, 21% for the IDENTITY semagace-
stat arms, 20% for the EXPEDITION placebo arms, and
18% for the EXPEDITION solanezumab arms. We found
no regional differences in SAE reporting.
Participant retention
The proportions of participants discontinuing prior to
trial completion were similar for the solanezumab (24%)
and placebo datasets (25%) in the EXPEDITION pro-
gram. In the IDENTITY program, discontinuation was
22% for the combined placebo arms but 46% for the
combined semagacestat arms. In each study program
(IDENTITY and EXPEDITION), the global regions dif-
fered in participant retention (P < 0.01 for each dataset
by χ2 test). For each study program, the dropout rate
was lowest in Japan (Table 5). The dropout rate was
highest in Eastern Europe/Russia for each placebo data-
set (39% in EXPEDITION and 41% in IDENTITY) and
the semagacestat treatment arms (51%). The dropoutrate was highest in North America for the solanezumab
active treatment arms (32%). Figure 1 illustrates the re-
sults of a time to discontinuation model, in which Japan
differed from at least one other region in placebo and
active treatment arms of each study program.
Across study programs and trial arms, the regions ap-
peared similar in the reasons for discontinuation. The
most common reasons for discontinuation were adverse
events, subject decision, and caregiver decision (Table 4).
Adverse events were the most frequent cause of discon-
tinuation and were consistently the most common cause
of discontinuation for each region in the IDENTITY ac-
tive treatment arms. In Eastern Europe/Russia and South
America/Mexico, subject decision was a more common




These results suggest that—despite strict protocols, ample
site training, and substantial trial monitoring—significant
heterogeneity should be expected among AD trial popula-
tions across geographic regions. Furthermore, we ob-
served patterns of regional similarities and differences for
participant demographics, scores on trial outcome mea-
sures at screening and baseline visits, TEAE reporting,
and study completion.
North America, Western Europe/Israel, and Australia/
South Africa were similar in their proportions of female
participants, carriers of the APOE ε4 genotype, and par-
ticipants enrolled with a spouse study partner. Propor-
tions different from this group but similar to each other
were observed for Asia, Eastern Europe/Russia, and South
America/Mexico for the same variables. Similar regional
patterns were observed when we compared scores on trial
outcomes at screening and baseline. Though consistent
patterns were evident, they seemed dependent upon
whether the outcome measure was based on informant
report. Participants from North America, Western Europe/
Israel, Japan, and Australia/South Africa had milder scores
for study partner–independent measures (that is, MMSE
at screening and baseline and the ADAS-cog11), whereas
participants from Asia, South America/Mexico, and
Eastern Europe/Russia had more moderate severity for
these outcomes. Eastern Europe/Russia had the most
severe scores for the CDR-SB; the mildest CDR-SB scores
were observed in Asia. Scores on informant-independent
outcomes were generally mildest in Australia/South Af-
rica; this region had the most severe scores on the NPI.
Asia and Japan, in contrast, demonstrated substantially
lower NPI scores than the remaining regions. Japan also
had the lowest frequency of reporting TEAEs for three
of the four datasets; Eastern Europe/Russia had lower
reporting frequency for the solanezumab arms of the
Table 3 Treatment-emergent adverse event rates per participant per month for combined trial arms among regionsa
Study program Treatment group North America Western Europe Australia/South Africa Japan Asia Eastern Europe/Russia South America/Mexico
IDENTITY Placebo 0.52 ± 1.31SA,EE,JP 0.37 ± 0.78EE,JP 0.34 ± 0.48 0.14 ± 0.17 WE,NA 0.31 ± 0.63 0.31 ± 0.84WE,NA 0.25 ± 0.56NA
Semagacestat 140 mg PO 1.10 ± 1.59EE,JP 0.76 ± 1.02EE 0.87 ± 0.85EE 0.57 ± 0.86NA 0.69 ± 0.89 0.62 ± 1.28AU,WE,NA 0.88 ± 1.36
EXPEDITION Placebo 0.40 ± 0.57SA,EE,JP,WE 0.24 ± 0.27SA,EE,NA 0.42 ± 0.31SA,EE, JP,WE 0.16 ± 0.13AU,NA 0.31 ± 0.42EE 0.19 ± 0.40AS,AU,WE,NA 0.22 ± 0.28AU,NA
Solanezumab 400 mg IV 0.41 ± 0.68SA,EE,JP,WE 0.24 ± 0.63NA 0.51 ± 1.04SA,EE 0.21 ± 0.22NA 0.29 ± 0.68EE 0.11 ± 0.13AS,AU,NA 0.19 ± 0.29AU,NA
aData are presented as mean ± standard deviation. SA = P < 0.01 vs South America/Mexico; EE = P < 0.01 vs Eastern Europe/Russia; AS = P < 0.01 vs Asia; JP = P < 0.01 vs Japan; AU = P < 0.01 vs Australia/South Africa;














Table 4 Most frequent reasons for drop out across global regionsa
Study
program

















decision = 9 (24%)
1. Participant decision =
4 (44%)
2. CG decision = 3 (27%) 2. AEs = 6 (30%) 2. AEs = 15 (28%) 2. CG decision = 3
(19%)









decision = 12 (14%)


















2. CG decision = 33
(26%)
2. Participant
decision = 14 (28%)
2. CG decision = 1 (17%) 2. Participant decision =
2 (20%)
2. AEs = 2 (18%) 2. AEs = 5 (21%) 2. AEs = 7 (25%)
2. Physician decision = 1
(17%)
2. Death = 2 (18%)
2. Death = 1 (17%)
Solanezumab
400 mg IV
1. CG decision = 39
(27%)





2. AEs = 34 (24%) 2. Participant
decision = 10 (24%)
2. Participant decision =
2 (18%)
2. CG decision = 4 (36%) 1. Participant
decision = 2
(25%)
2. AEs = 3 (21%) 2. AEs = 5 (24%)



































IDENTITY Placebo 291 (76.4)EE 162 (81.4)EE 37 (80.4) 99 (90.0)EE 79 (79.8) 79 (59.4) 70 (81.4)
Semagacestat
140 mg PO
198 (50.8) 129 (60.9) 29 (53.7) 69 (64.5) 58 (60.4) 69 (48.9) 31 (37.8)
EXPEDITION Placebo 325 (72.1) 163 (76.5) 32 (84.2) 71 (87.7) 59 (84.3) 38 (61.3) 82 (74.6)
Solanezumab
400 mg IV
303 (67.8)JP 175 (80.7) 35 (76.1) 89 (89.0) 57 (87.7) 43 (75.4) 74 (77.9)
aData are presented as count (%). EE = P < 0.01 vs Eastern Europe; JP = P < 0.01 vs Japan; IV = Intravenously; PO = By mouth.
Figure 1 Time to discontinuation models. In time to early discontinuation models for each study program arm, Japan differed significantly from
South America/Mexico in the IDENTITY active semagacestat arms (A), from Asia and Eastern Europe/Russia in the IDENTITY placebo arms (B), from
North America in the EXPEDITION active solanezumab treatment arms (C), and from Eastern Europe/Russia for the EXPEDITION placebo arms
(D) (P< 0.01 for all comparisons by log-rank test). Eastern Europe/Russia differed from Australia/South Africa, North America, and Western Europe/Israel in
the IDENTITY placebo arms (P< 0.01 by log-rank test). South America/Mexico differed from Western Europe/Israel in the IDENTITY active semagacestat
arms (P< 0.01 by log-rank test).
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was in North America and Australia/South Africa.
Potential explanations for the observed heterogeneity
We hypothesize that several factors that are not mutually
exclusive contributed to the observed heterogeneity. First,
the regions in which participants were recruited are differ-
ent. Geographic regions differ in lifestyle factors, overall
health, and causes of death and disability [32,33]. It is
likely that access to medical care and the sophistication
of that care differ among geographic regions. The popula-
tions recruited to these studies may accurately represent
differences among the disease-suffering populations in dif-
ferent parts of the world. For example, North American
participants had substantially higher levels of education
than did those in South America/Mexico and Asia, as is
the case for the countries in these regions [3]. It is import-
ant to note, however, that in North America—and prob-
ably every other region—trials are subject to sample bias.
In the United States, trial populations are consistently
more educated than the general population. Thus, these
findings may reflect regional differences in population
demographics as well as regional differences in the degree
of sample bias; that is, patient access to trials and willing-
ness to participate may differ among regions.
Regional differences in AD diagnosis, care, and reim-
bursement may also have contributed to the observed
heterogeneity. Until recently, the only AD therapy that
had received regulatory approval in Japan was donepezil
[34]. This may explain or contribute to the low fre-
quencies of memantine and dual therapy in Japan. Other
regional differences in standard of care or physician reim-
bursements for diagnostic visits or procedures could
similarly impact the stage of disease at which a formal
diagnosis is made, and this could have an impact on
variables such as time from symptom onset to trial screen-
ing and baseline disease severity. In fact, the regions with
the shortest times from symptom onset and diagnosis to
screening (Japan and Eastern Europe/Russia) did not have
milder scores on baseline trial outcome measures than the
regions with longer durations. Eastern Europe/Russia had
the most severe scores at baseline. North America had the
longest duration of symptoms and time since diagnosis
to enrollment, but it had among the mildest scores on
informant-independent baseline outcomes. Possible ex-
planations for such discrepancies could be differing rates
of disease progression among regions, differing access to
medical care, or earlier detection in some regions, though
this will require further study.
Regional variation in research infrastructure or the
expertise of investigators could also have contributed to
the observed heterogeneity. For example, the availabil-
ity of experienced raters at sites varied across regions
and such differences might impact mean scores orvariability on trial outcomes at baseline. We cannot as-
sume that differences in investigative teams explain the
observed differences, however; it is possible that differ-
ences in patients, informants, outcomes (when trans-
lated, for example), and raters exist.
Translation of outcome measures does not guarantee
equivalence among cultural groups or regions [35]. Local
customs and standards may necessitate adjustment [36]
or replacement [37] of particular items. For example, one
Chinese version of the ADAS-cog used pictures instead
of words for assessing memory performance [38]. Alter-
natively, findings from some studies suggest that differ-
ing cutoffs may be appropriate when applying common
scales to differing geographic, ethnic, and cultural pop-
ulations [39]. Even within geographic regions, as defined
in the present study, challenges related to harmonization
and validation of outcome measures may occur, poten-
tially further increasing trial data variance [40]. In the
studies examined here, scales were kept consistent to
the greatest extent possible to facilitate combining study
data; only in certain circumstances were sites permitted to
alter scales for regional differences (for example, substitut-
ing region or burro for county, where counties were not
present, on the MMSE).
Regional and cultural differences in family attitudes to-
ward AD recognition, diagnosis, treatment, reporting of
symptoms, and research participation may have contrib-
uted to the observed heterogeneity. In North America,
Western Europe/Israel, and Australia/South Africa, patients
with a spouse made up a majority of the participants and
proportionately more men were enrolled. In contrast,
the majority of participants in Eastern Europe/Russia
and South America/Mexico enrolled with a nonspouse
study partner. It is not clear whether regional differ-
ences exist in the proportions of caregiver types or if
caregiver attitudes inhibit participation by nonspousal
partners in some regions and enhance it in others. Cultural
differences among caregivers may also have impacted in-
formant reporting in the trials. TEAE reporting and scores
on the CDR-SB and NPI were consistently lower for Asia
and Japan, relative to the other regions, similar to previous
observations [41].
Finally, regional ethnogenetic differences in disease may
have contributed to the observed heterogeneity. This is
most pertinent to the observed frequencies of APOE
genotypes. The APOE ε4 genotype is the best replicated
and most understood genetic risk factor for AD [42], but
the impact of APOE (and other) genotypes on AD risk in
different ethnic groups remains unclear [43]. APOE ε4
prevalence may differ regionally, possibly accounting
for the difference in ε4 proportions observed in these
analyses. For example, fewer participants carried APOE
ε4 in Asia than in other regions, a finding similar to
that of previous studies of APOE prevalence [44,45].
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genetic risk for disease [46]. Here, APOE ε4 differences
did not seem to predict differences in mean age between
regions. North America had the highest rate of ε4 carriers
and the oldest mean age, whereas Eastern Europe/Russia
had the second-lowest proportion of ε4 carriers and a
younger mean age than the other global regions. To the
extent that drug interactions with genotype impact the
safety [47] or efficacy of AD treatments [48-50], ethnoge-
netic differences within trial samples should be considered
when implementing multinational trials. Differences in
the proportions of ε4 carriers and noncarriers could also
have specific implications for trials of antiamyloid therap-
ies because noncarrier participants may more frequently
fail to demonstrate amyloid burden when studied with
amyloid imaging [51].Limitations
These data are among the first of their kind, and several
limitations should be considered. Our observations do
not provide evidence for why heterogeneity exists. Though
we provide hypotheses related to factors that may contrib-
ute to the observed regional differences, these hypotheses
require further research to better guide sponsors of multi-
national AD trials. Furthermore, because these study pro-
grams were not designed to evaluate regional differences,
several data elements important to sponsors designing
global trials were not sufficiently available to permit ana-
lysis, including regulatory startup variables such as time
to institutional review board approval or contract nego-
tiation, the type of sites and investigators within each glo-
bal region, and participant data on socioeconomic status.
The grouping of regions was based on geography, infor-
mation in the published literature [5], and the experiences
of the research team, and with data limitations in mind.
Specifically, low numbers of participants in some coun-
tries or regions necessitated combinations to improve stat-
istical power. This limitation may be minimized by the
findings of significant regional differences. Were the data
homogeneous, the assignment of regions, even if arbitrary,
would not be expected to produce statistically significant
differences among groups. The pattern of differences that
we observed may not be the same in future datasets,
however, so our results cannot be used to predict future
findings in a specific region or country. Other strategies
for assigning global regions, including ethnic or genetic
groupings, might also be reasonable and could produce
alternate findings.
Finally, although many of the differences between re-
gions are statistically significant, it is unclear to what ex-
tent they are clinically meaningful or interfere with the
ability to measure a drug effect. In the IDENTITY stud-
ies, for example, the cognitive worsening associated withsemagacestat treatment was identified despite population
heterogeneity.
Impact
We performed these analyses to provide sponsors with
data to assist with planning and conducting trials in
multiple geographic regions. The data indicate that study
populations differ across regions from a demographic
perspective. Similarly, APOE ε4 carrier status differed
among regions in these trials, and this may bear on the
number of non-AD patients entering trials that do not
utilize AD biomarkers as entry criteria. Screening and
baseline scores on the outcome measures we examined
differed among regions, again indicating the heterogen-
eity of multinational trial populations. The difference in
TEAE reporting and dropout among regions is consist-
ent with findings from a previous analysis by country of
the IDENTITY trial data [52]. These data suggest that
heterogeneity will be present and should be accounted
for when developing multinational AD trials. Although
researchers generally attempt to avoid heterogeneity in
clinical trials to facilitate identifying a drug effect if one
exists, heterogeneity may also provide confidence that
an observed drug effect is real and that treatment will
be effective in the general clinical population, where
heterogeneity will be the norm.
Conclusions
To meet regulatory and enrollment needs, sponsors of
studies in AD and other serious diseases are increasingly
implementing multinational clinical trials. Our data sug-
gest that this may contribute to sample heterogeneity. Be-
cause trial designs and sample sizes are dependent upon
expected population variance, these results suggest that
(1) sponsors may wish to limit the number of regions from
which sites outside the United States recruit participants
to reduce variance, (2) multinational trials may need to be
large enough to account for potentially increased variance,
and (3) sponsors must carefully consider which countries
and regions to include when planning multinational trials.
For example, trials of interventions to reduce or prevent
neuropsychiatric symptoms may face additional challenges
in Japan and Asia, given lower reporting of these symp-
toms in those regions. Sponsors may also consider balan-
cing enrollment sites, based on the knowledge of which
regions are likely to enroll similar patients in terms of age,
body size, genotypes, and concomitant therapies.
Although differences in the proportion of participants
receiving anti-AD medications among the regions were
evident, more than 70% of patients in each region were
taking at least one anti-AD medication. This suggests that
trial designs that seek to enroll drug-naïve participants will
have increasingly challenging recruitment, even when
enrolling non-US populations [4]. Moreover, to the extent
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therapies, these data may instruct selection of regional
sites.
To develop desperately needed new drugs for AD, high-
quality clinical trials must be performed in a rapid man-
ner. The conduct of multinational trials accelerates patient
recruitment and enables broader registration and eventual
patient access, but it introduces variables that have
not been completely delineated and are incompletely
understood. Trial sponsors must carefully consider
potential effects on trial data and implement strategies
to identify those factors that can be mitigated to re-
duce variability.
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